Abstract:Abstract The CEllular Thermal Shift Assay (CETSA) technology is a powerful way to assess target engagement across various matrixes. By the introduction of the high-throughput format (CETSA Navigate HT), this technology offers a reliable high-throughput screening method in natural cellular environments that can successfully be applied in compound screening for hit identification and confirmation already during lead generation. Due to its broad applicability to native, full length protein targets in the live cellular environment, without the need for expensive and time-consuming protein and/or compound labelling efforts, CETSA Navigate HT may be regarded as a new paradigm for high-throughput screening and actives generation. As a case study to demonstrate the applicability of CETSA Navigate HT in hit identification, we have applied the technology for primary screening of a 12000 compound library for CDK4, a protein targeted in several cancers. Hits identified from this screen are privileged from the onset by binding to the target in a physiologically relevant cellular matrix and in a binding-mode agnostic way. This is in contrast to traditional screening methods targeting activity or in vitro interactions where cellular activity is addressed in later stages. Data from follow up studies using functional assays will be presented as well as mass spectrometry based CETSA selectivity profiling and comparison to commercially available de novo CDK4/6 inhibitors. Citation Format: Helena Almqvist, Victoria Brehmer, Laurence Arnold, Tomas Friman, Stina Lundgren, Daniel Martinez Molina. CETSA Navigate HT: A new paradigm for high-throughput screening [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3096.

Application of High-Throughput Flow Cytometry in Early Drug Discovery: An AstraZeneca Perspective

Automated High-Throughput Flow Cytometry for High-Content Screening in Antibody Development

Computational analysis of high-throughput flow cytometry data

A Scalable Pipeline for High-Throughput Flow Cytometry

Applications of Flow Cytometry in Drug Discovery and Translational Research

Design and Implementation of High Throughput Screening Assays for Drug Discoveries

Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1

From big flow cytometry datasets to smart diagnostic strategies: The EuroFlow approach

High-throughput mechanistic screening of non-equilibrium inhibitors by a fully automated data analysis pipeline in early drug-discovery

Potential and challenges of clinical high‐dimensional flow cytometry: A call to action

The development of high-content screening (HCS) technology and its importance to drug discovery

Abstract 3096: CETSA Navigate HT: A new paradigm for high-throughput screening

High-Throughput Flow Cytometry Drug Combination Discovery with Novel Synergy Analysis Software, SynScreen

High-Throughput Cellular Thermal Shift Assays in Research and Drug Discovery

High Throughput Screening of Chromatographic Phases for Rapid Process Development

Ultra High-Throughput Multiparametric Imaging Flow Cytometry: Towards Diffraction-Limited Sub-Cellular Detection

Development and Application of Activity-based Fluorescent Probes for High-Throughput Screening

Current progress in high-throughput screening for drug repurposing

A robust CETSA data analysis automation workflow for routine screening

Target-based drug discovery: Applications of fluorescence techniques in high throughput and fragment-based screening

Mass Cytometry: A Highly Multiplexed Single-Cell Technology for Advancing Drug Development